Less Ads, More Data, More Tools Register for FREE

Pin to quick picksConcurrent Technologies Regulatory News (CNC)

Share Price Information for Concurrent Technologies (CNC)

Share Price is delayed by 15 minutes
Get Live Data
252.50    2.50 (1.00%)
Bid:
250.00
Ask:
255.00
Spread: 5.00 (2.00%)
Market Cap: £229.38m
CNC Live PriceLast checked at - London Stock Exchange

Intraday Concurrent Technologies Share Chart

Trading Update

Today 07:00

RNS Number : 9762L
Concurrent Technologies PLC
13 July 2026
 

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a Regulatory Information Service, this information is considered to be in the public domain.

 

13 July 2026

Concurrent Technologies Plc

("Concurrent", the "Company" or the "Group")

 

Trading Update

 

Record H1 performance and strong order momentum

 

Concurrent Technologies Plc (AIM: CNC), a designer and manufacturer of leading-edge computer products, systems and mission critical solutions used in high-performance markets by some of the world's major OEMs, provides an update on trading for the six months to 30 June 2026 ("H1 FY26").

 

Based on its unaudited management accounts for H1 FY26, the Company expects to report record results for a first half, with revenue of approximately £23.1m (H1 FY25: £21.1m) and profit before tax of approximately £3.3m (H1 FY25: £2.7m).

 

Order intake for H1 FY26 was significantly ahead of the prior year at £46.9m, up 110% (H1 FY25 £22.3m), driven by demand across the Group's key geographies and end markets. This included the c.£17m multi-year order secured from a European customer announced in June 2026. Excluding this order, the Group nevertheless achieved record order intake compared to any prior half-year period.

 

The Systems business secured approximately $8m of orders during the period and delivered a profitable first half. The business continues to make progress and is expected to become an increasingly material contributor to Group performance over the medium term. The Products business experienced more modest order intake in the first quarter, followed by an improvement in the second quarter, providing greater revenue visibility into the second half.

 

During H1 FY26, the Group continued to secure further design wins across both its Products and Systems businesses, with a projected lifetime value (LTV) of approximately £129m. These design wins enhance medium-term revenue visibility and underpin the Group's future growth pipeline.

 

The Group is also seeing increased conversion of earlier design wins, secured three to four years ago, into production orders, supporting the transition of pipeline opportunities into revenue.

 

To support anticipated demand, the Group's Colchester manufacturing expansion is progressing to plan, with output capacity expected to approximately double from Q3 2026.

 

The Group has continued to proactively manage industry-wide supply chain challenges, including securing supplier commitments for forecast DRAM requirements through 2026 and into 2027. In addition, following accelerated end-of-life announcements affecting certain Intel processor families, the Group has worked closely with customers and suppliers to secure future programme requirements through appropriate forward procurement arrangements.

 

The Company has entered H2 FY26 with good momentum, demonstrated by the $9.4m contract win announced post period end. Combined with a healthy backlog and pipeline and the expected conversion of design wins into production in H2, the Board believes that the Company is well positioned to at least deliver full year results for 2026 in line with current market expectations*.

 

Miles Adcock, CEO of Concurrent Technologies, commented: "Delivering record first-half results reflects the continued strength of demand across our key markets and the successful execution of our growth strategy across both Products and Systems. The increasing conversion of earlier design wins into production orders, as anticipated, is particularly encouraging, alongside continued new programme wins, which together are enhancing the visibility and quality of future revenues across the Group.

 

"Underlying demand remains strong, and alongside a solid order book, the Group is well positioned for the second half of the year and beyond."

 

*In so far as the Board is aware, consensus market expectations for FY26 are revenues of £53m and profit before tax of £8m.

 

The person responsible for the release of this announcement is Miles Adcock, CEO of Concurrent.

 

Enquiries:

 

Concurrent Technologies Plc Miles Adcock - CEO

Kim Garrod - CFO

 

 

+44 (0)1206 752626

 

Alma Strategic Communications Hannah Campbell / Josh Royston / Will Merison

 

+44 (0)20 3405 0205

 

Investec Bank plc (Financial Adviser, Nominated Adviser and Corporate Broker) Nick Prowting / Virginia Bull / Arnav Kapoor / Tommy Jackson

+44 (0)20 7597 5970

About Concurrent Technologies Plc

Concurrent Technologies Plc develops and manufactures high-end embedded plug-in cards and systems for use in a wide range of high-performance, long-life cycle applications within the telecommunications, defence, security, telemetry, scientific and aerospace markets, including applications within extremely harsh environments. The processor products feature Intel® processors, including the latest generation embedded Intel® Core™ processors, Intel® Xeon® and Intel Atom™ processors. The products are designed to be compliant with industry specifications and support many of today's leading embedded operating systems. The products are sold world-wide.

For more information on Concurrent Technologies Plc and its products please visit www.concurrent.tech.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTRTMTTMTIBBFF
Date   Source Headline
1st Aug 202310:58 amRNSNew Product Announcement
20th Jul 20237:00 amRNSNotification of Major Holdings
18th Jul 20237:00 amRNSPosting of Annual Report and Notice of AGM
17th Jul 20237:00 amRNSPost-Close Trading Update
30th Jun 20237:00 amRNSResults for the year ended 31 December 2022
19th Jun 20237:00 amRNSUpdate on Audited Annual Results
12th Jun 20237:00 amRNSSignificant Systems Win
9th Jun 20235:11 pmRNSNotification of Major Holdings
7th Jun 20237:00 amRNSNew Distributor Agreement
5th Jun 20237:00 amRNSNotice of Results
24th Mar 20237:00 amRNSNew Product Announcement
21st Mar 20237:00 amRNSReseller Agreement
4th Jan 20237:00 amRNSPost-Close Trading Update
14th Dec 20227:00 amRNSPartnership Agreement
28th Oct 20227:00 amRNSIssue of Share options and PDMR dealing
5th Oct 20227:00 amRNSConcurrent Technologies Enters the Systems Market
26th Sep 20227:00 amRNSInterim Results
12th Sep 20227:00 amRNSNotice of Interim Results
24th Aug 202210:29 amRNSHolding(s) in Company
24th Aug 202210:27 amRNSHolding(s) in Company
19th Aug 202212:06 pmRNSHolding(s) in Company
13th Jul 20227:00 amRNSSupply Agreement
29th Jun 202212:55 pmRNSResult of AGM
30th May 20227:00 amRNSPosting of Annual Report & Notice of AGM
23rd May 20222:46 pmRNSIssue of Share options and PDMR dealing
12th May 20227:00 amRNSResults for the year ended 31 December 2021
11th May 20227:00 amRNSInvestor Presentation
9th May 20227:00 amRNSConfirmation of Results Date and Board Appointment
24th Mar 202212:44 pmRNSNotice of Results
9th Mar 202210:36 amRNSContract Award
25th Feb 20227:00 amRNSProduct Announcement
21st Feb 20227:00 amRNSBoard Changes
26th Jan 20227:00 amRNSProduct Announcement
5th Jan 20227:00 amRNSPost-Close Trading Update
23rd Nov 20217:07 amRNSIssue of Share Options and PDMR Dealing
27th Sep 20213:12 pmRNSBoard Changes
7th Sep 20217:00 amRNSBoard Changes
7th Sep 20217:00 amRNSInterim Results
1st Sep 20211:20 pmRNSNotice of Results
10th Aug 202112:05 pmRNSHolding(s) in Company
4th Aug 20217:00 amRNSProduct Announcement
21st Jul 20217:00 amRNSBoard Changes
8th Jul 202111:15 amRNSHolding(s) in Company
23rd Jun 202111:58 amRNSIssue of share options and PDMR dealing
15th Jun 20214:19 pmRNSResult of AGM
15th Jun 202112:34 pmRNSAGM Statement
20th May 20217:00 amRNSPosting of Annual Report & Notice of AGM
12th May 20219:00 amRNSBoard Changes
12th Apr 20217:00 amRNSFinal Results
25th Mar 202110:50 amRNSNotification of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.